Shingrix In Recipients of Allogeneic Transplants

Exclusion Criteria

• •Active Graft Versus Host Disease (aGVHD) at the time of enrollment and receipt of the third dose of RZV
• •Having received ≥20 mg prednisone for more than 2 weeks (or equivalent) in the 8 weeks preceding enrollment.
• •Receiving any significant immunosuppressive therapy other than for graft maintenance, in the opinion of the investigator.
• •Having received a live attenuated vaccine within the last 4 weeks, or inactivated vaccine in the last 2 weeks, prior to enrollment.
• •Having a history of HZ after the administration of the primary 2-dose RZV immunization regimen.
• •Pregnancy or breastfeeding
• •Receiving investigational drugs from 30 day before enrollment or planned during the study
• •Inability of participants unable to comply with the study schedule in the opinion of the investigator